Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMLM28-A4 lasmotinib plus venetoclax and azacitidine for newly diagnosed FLT3-ITD acute myeloid leukemia
ACTRN12626001334392Phase 2Not yet recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lasmotinib in acute myeloid leukemia (AML) (3 arms), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoints: Recommended phase 2 dose and Composite remission rate. Planned start May 2027; status: not yet recruiting.
02
Drugs
lasmotinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ACTRN12626001334392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626001334392.